Clinical Trial Update: Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients [Phase 2]

View source ↗

Summary

Phase 2 study of URC102 to assess efficacy and safety in gout and hyperuricemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• URC102 (URC102)

Snippet

Sponsor: JW Pharmaceutical | Conditions: Gout, Hyperuricemia | Phase 2 | Status: COMPLETED